Literature DB >> 1796051

Formulation, bioavailability, and pharmacokinetics of sustained-release potassium chloride tablets.

S Senel1, Y Capan, T Dalkara, N Inanç, A A Hincal.   

Abstract

The release of potassium chloride incorporated into hydrogenated vegetable oil and hydroxypropyl methylcellulose matrix tablets was studied in vitro. The formulations containing 20% hydrogenated vegetable oil and hydroxypropyl methylcellulose showed a sustained-release profile comparable to that of a standard commercially available sustained-release preparation, containing 8 mEq potassium chloride embedded in a wax material. The formulated and standard sustained-release potassium chloride tablets were compared to a conventional enteric-coated potassium chloride tablet in 10 healthy subjects. Mean recoveries in 24-hr urine potassium levels from four dosage forms (after subtracting normal urine potassium excretion levels) were 76 +/- 32% from hydroxypropyl methylcellulose, 95 +/- 22% from hydrogenated vegetable oil-incorporated matrix tablets, 91 +/- 29% from commercially available sustained-release tablets, and 97 +/- 13% from enteric-coated tablets. There was no significant difference (P greater than 0.05) in the time to reach maximum excretion rates among the three sustained-release tablets. No significant adverse effect was experienced with any of the preparations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1796051     DOI: 10.1023/a:1015868232590

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

1.  An in vitro dissolution test for slow release potassium chloride tablets.

Authors:  A C Cartwright; C Shah
Journal:  J Pharm Pharmacol       Date:  1977-06       Impact factor: 3.765

2.  SMALL-BOWEL ULCERATION APPARENTLY ASSOCIATED WITH THIAZIDE AND POTASSIUM THERAPY.

Authors:  D R BAKER; W H SCHRADER; C R HITCHCOCK
Journal:  JAMA       Date:  1964-11-16       Impact factor: 56.272

3.  Comparative effects of three delivery systems of oral potassium on upper gastrointestinal mucosa.

Authors:  J C McLoughlin
Journal:  Br J Clin Pract       Date:  1987-08

4.  Bioavailability of potassium from a slow-release tablet.

Authors:  D Ben-Ishay; K Engelman
Journal:  Clin Pharmacol Ther       Date:  1973 Mar-Apr       Impact factor: 6.875

5.  Bioavailability and pharmacokinetics of a new, slow-release potassium chloride capsule.

Authors:  J Arnold; J T Jacob; B Riley
Journal:  J Pharm Sci       Date:  1980-12       Impact factor: 3.534

6.  Analysis of Fickian and non-Fickian drug release from polymers.

Authors:  N A Peppas
Journal:  Pharm Acta Helv       Date:  1985

7.  The comparative bioavailability of liquid, wax-matrix, and microencapsulated preparations of potassium chloride.

Authors:  V A Skoutakis; S R Acchiardo; N J Wojciechowski; C A Carter; A P Melikian; A N Chremos
Journal:  J Clin Pharmacol       Date:  1985 Nov-Dec       Impact factor: 3.126

8.  Potassium chloride and intestinal ulceration.

Authors:  V Wynn
Journal:  Lancet       Date:  1965-12-11       Impact factor: 79.321

9.  Bioavailability and pharmacokinetics of a new sustained-release potassium chloride tablet.

Authors:  C J Betlach; J D Arnold; R W Frost; P T Leese; M A Gonzalez
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

10.  Potassium physiology.

Authors:  S O Thier
Journal:  Am J Med       Date:  1986-04-25       Impact factor: 4.965

View more
  1 in total

1.  Development and bioequivalence study of potassium chloride extended release tablets.

Authors:  Thu Van Le Thi; Nghiem Le Quan; Hau Le
Journal:  Asian J Pharm Sci       Date:  2017-10-23       Impact factor: 6.598

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.